SEC Filing Summary: Rexahn Pharmaceuticals, Inc. (8-K)
Business Context and Reporting Period
This Form 8-K Current Report was filed by Rexahn Pharmaceuticals, Inc. on December 21, 2017, regarding events occurring on December 15, 2017. The filing addresses corporate governance matters, specifically the scheduling of the 2018 Annual Meeting of Stockholders and the deadlines for shareholder proposals. Note: The input metadata referenced "Opus Genetics, Inc.," but the filing text explicitly identifies the registrant as Rexahn Pharmaceuticals, Inc.
Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report is limited to corporate governance notifications and contains no financial performance data.
Material Changes
There are no material financial changes reported in this document. The primary update is the establishment of the date for the 2018 Annual Meeting of Stockholders.
Guidance, Outlook, and Management Commentary
Management has set the date for the 2018 Annual Meeting of Stockholders as June 14, 2018. The filing outlines specific deadlines for shareholder proposals:
- Proxy Inclusion Deadline: Proposals intended for inclusion in the Company's proxy materials must be received by January 4, 2018.
- Advance Notice Deadline: Proposals to be presented at the meeting without inclusion in proxy materials must be received between February 14, 2018 and March 16, 2018.
No financial guidance, risk factors, or contingencies are disclosed in this specific filing.
Key Facts for Investor Verification
- Verify the correct registrant name is Rexahn Pharmaceuticals, Inc., not Opus Genetics, Inc.
- Confirm the 2018 Annual Meeting date is June 14, 2018.
- Note the strict deadlines for submitting shareholder proposals (January 4, 2018, for proxy inclusion; February 14–March 16, 2018, for advance notice).
- Recognize that this filing contains no financial results or operational updates.